To define and validate “optimal recovery” (OR) as a multidimensional composite endpoint for gastric cancer surgery, identify its predictors, and evaluate its correlation with postoperative quality of life (QOL) compared to traditional indicators. In this single-center retrospective cohort study, 456 patients undergoing curative-intent gastrectomy were analyzed. Optimal recovery was defined as simultaneous achievement of five criteria: no major complications (Clavien-Dindo ≥ III), flatus by postoperative day (POD) 3, independent ambulation ≥ 30 min by POD 3, tolerance of semi-liquid diet without intravenous support by POD 6, and discharge by POD 7 without 30-day re-admission. Multivariable logistic regression identified OR predictors. Multiple linear regression compared OR, complications, and length of stay (LOS) in predicting 30-day QOL (EORTC QLQ-C30/STO22). Optimal recovery was achieved in 218 patients (47.8%). Independent predictors included: preoperative prognostic nutritional index (PNI) ≥ 45 (p < 0.001), modified Glasgow prognostic score (mGPS) 0 (p = 0.006), distal gastrectomy (p = 0.011), and operation time ≤ 180 min (p < 0.001). In predicting 30-day global health status, optimal recovery alone explained 28.3% of variance (adjusted r²=0.283), outperforming models with complications alone (r²=0.182), LOS alone (r²=0.152), or both (r²=0.201). OR patients reported significantly better QOL across physical, role, and symptom domains (all p < 0.001). Optimal recovery is a stringent, patient-centered endpoint that reflects high-quality convalescence. Its predictors are clinically modifiable, and it correlates more strongly with early QOL than traditional surgical metrics, supporting its use as a benchmark for surgical quality and a target for prehabilitation. Definition, predictors, and quality-of-life impact of Optimal Recovery (OR) after gastric cancer surgery. Left panel: OR is a composite endpoint requiring simultaneous achievement of five criteria: no major complications (Clavien–Dindo<III), flatus by postoperative day (POD) 3, independent ambulation ≥30 minutes by POD 3, tolerance of semi-liquid diet without intravenous support by POD 6, and discharge within 7 days without readmission. Center panel: OR was achieved in 47.8% (218/456) of patients. Independent predictors included preoperative prognostic nutritional index ≥45 (odds ratio [OR] 2.38), modified Glasgow prognostic score of 0 (OR 1.96), distal gastrectomy (OR 1.82), operation time ≤180 minutes (OR 2.63), and younger age (OR 0.96 per year). Right panel: Patients achieving OR reported significantly better 30‑day quality of life across multiple domains (EORTC QLQ-C30/STO22). The OR composite explained 28.3% of variance in global health status, substantially outperforming traditional metrics (complications alone: 18.2%; length of stay alone: 15.2%). All text in Times New Roman. POD, postoperative day; PNI, prognostic nutritional index; mGPS, modified Glasgow prognostic score; QOL, quality of life; LOS, length of stay We define "Optimal Recovery" as a novel composite endpoint for gastric cancer surgery requiring simultaneous achievement of five milestones: no major complications, flatus by day 3, independent ambulation by day 3, oral nutrition by day 6, and discharge within 7 days without readmission. Nearly half (47.8%) of patients achieved this stringent definition. Four independent predictors—PNI, mGPS, operation time, and distal gastrectomy—represent actionable targets for precision prehabilitation. Patients with poor nutritional or inflammatory status (PNI <45 or mGPS ≥1) have substantially lower odds of achieving optimal recovery and should receive targeted preoperative optimization. Optimal recovery strongly predicts 30-day quality of life and outperforms traditional surgical metrics. The composite endpoint explains 28.3% of variance in global health status--a 55% relative improvement over complication-based models--and captures patient experience dimensions that conventional indicators miss, particularly eating restrictions, physical function, and appetite loss.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: